Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Rios-Hoyo, Alejandro
- dc.contributor.author Monzonis-Hernández, Xavier
- dc.contributor.author Vidal Barrull, Joana
- dc.contributor.author Linares, Jennifer
- dc.contributor.author Montagut Viladot, Clara
- dc.date.accessioned 2025-05-28T06:00:58Z
- dc.date.available 2025-05-28T06:00:58Z
- dc.date.issued 2024
- dc.description.abstract Emergence of acquired resistance limits the efficacy of the anti-EGFR therapies cetuximab and panitumumab in metastatic colorectal cancer. In the last decade, preclinical and clinical cohort studies have uncovered genomic alterations that confer a selective advantage to tumor cells under EGFR blockade, mainly downstream re-activation of RAS-MEK signaling and mutations in the extracellular domain of EGFR (EGFR-ECD). Liquid biopsies (genotyping of ctDNA) have been established as an excellent tool to easily monitor the dynamics of genomic alterations resistance in the blood of patients and to select patients for rechallenge with anti-EGFR therapies. Accordingly, several clinical trials have shown clinical benefit of rechallenge with anti-EGFR therapy in genomically-selected patients using ctDNA. However, alternative mechanisms underpinning resistance beyond genomics -mainly related to the tumor microenvironment-have been unveiled, specifically relevant in patients receiving chemotherapy-based multi-drug treatment in first line. This review explores the complexity of the multifaceted mechanisms that mediate secondary resistance to anti-EGFR therapies and potential therapeutic strategies to circumvent acquired resistance.
- dc.format.mimetype application/pdf
- dc.identifier.citation Ríos-Hoyo A, Monzonís X, Vidal J, Linares J, Montagut C. Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road. Front Pharmacol. 2024 Apr 22;15:1398419. DOI: 10.3389/fphar.2024.1398419
- dc.identifier.doi http://dx.doi.org/10.3389/fphar.2024.1398419
- dc.identifier.issn 1663-9812
- dc.identifier.uri http://hdl.handle.net/10230/70532
- dc.language.iso eng
- dc.publisher Frontiers
- dc.relation.ispartof Front Pharmacol. 2024 Apr 22;15:1398419
- dc.rights © 2024 Ríos-Hoyo, Monzonís, Vidal, Linares and Montagut. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. http://creativecommons.org/licenses/by/4.0/
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword CtDNA
- dc.subject.keyword Acquired resistance
- dc.subject.keyword Anti-EGFR
- dc.subject.keyword Anti-EGFR rechallenge
- dc.subject.keyword Clonal dynamics
- dc.subject.keyword Colorectal cancer
- dc.subject.keyword Liquid biopsy
- dc.subject.keyword Tumor heterogeneity
- dc.title Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion